Reference : European regulatory perspectives for innovative therapies.
Scientific journals : Article
Human health sciences : General & internal medicine
European regulatory perspectives for innovative therapies.
Ormarsdottir, S. [> > > >]
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Abadie, Eric [AFSSAPS (France) > > > >]
Osteoporosis International
Springer Science & Business Media B.V.
Yes (verified by ORBi)
United Kingdom
[en] Bone Density Conservation Agents/therapeutic use ; Controlled Clinical Trials as Topic/standards ; Drug Approval/legislation & jurisprudence ; Drug Industry ; Europe ; European Union ; Humans ; Legislation, Drug/trends ; Osteoporosis/drug therapy ; Technology, Pharmaceutical/legislation & jurisprudence/trends
[en] The current regulatory requirements offer accelerated assessment of innovative therapies in Europe. Future perspectives include the need for increased interaction between stakeholders in pharmaceutical development. Development of new, high quality, effective and safe medicines in Europe is the common goal of academia, pharmaceutical industry and regulatory authorities. To achieve this, it is important that regulatory requirements do not hinder innovation and vice versa, innovation cannot be allowed to proceed without concerns for public health. Interaction between stakeholders in pharmaceutical development is of the utmost importance. A dialogue has begun and in the future it will be the responsibility of all stakeholders to ensure continuous exchanges in an environment that is characterised by new scientific advances and global development programmes.

File(s) associated to this reference

Fulltext file(s):

Restricted access
European regulatory perspectives for innovative therapies.pdfNo commentaryPublisher postprint139.06 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.